Fate Therapeutics (FATE) Gains from Sales and Divestitures (2013 - 2014)
Fate Therapeutics (FATE) reported Gains from Sales and Divestitures of $27123.0 for Q4 2014, down 22.57% on a YoY basis from $35027.0 in Q4 2013, and down 22.57% quarter-over-quarter from $35027.0 in Q4 2013.
Fate Therapeutics (FATE) Gains from Sales and Divestitures (2013 - 2014) Analysis & Trends
Fate Therapeutics has reported Gains from Sales and Divestitures for 2 years, with the latest figure at $27123.0 in Q4 2014.
- For the quarter ending Q4 2014, Gains from Sales and Divestitures fell 22.57% year-over-year to $27123.0; the trailing twelve-month figure through Dec 2014 stood at $27123.0 (down 22.57% YoY), and the FY2014 full-year result was $27123.0, down 22.57% from the prior year.
- Gains from Sales and Divestitures for Q4 2014 stood at $27123.0, down from $35027.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $35027.0 in Q4 2013, with the low at $27123.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Fate Therapeutics | 250.86 Mn | 250.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 27,123.00 |
| Dec 31, 2014 | 27,123.00 |
| Dec 31, 2013 | 35,027.00 |
| Dec 31, 2013 | 35,027.00 |